Dashboard
Manage Tickers

BGNEBeiGene, Ltd.

Nasdaq beigene.com


$ 162.98 $ -3.40 (-2.04 %)    

Friday, 14-Jun-2024 15:59:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 3.08 (0.65 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.20 (0.04 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 162.58
$ 162.84
$ 0.00 x 0
$ 0.00 x 0
$ 160.76 - $ 163.42
$ 126.97 - $ 225.23
314,022
na
17B
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 02-28-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-22-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-10-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

beigene-says-it-will-present-new-data-from-sequoia-study-evaluating-brukinsa-plus-venetoclax-in-high-risk-first-line-cllsll-at-eha2024-preliminary-data-suggests-efficacy-and-tolerability
BeiGene Says It Will Present New Data From...
06/14/2024 10:04:40

BeiGene, Ltd. a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutin...

Core News & Articles
BriaCell Therapeutics Announces Clinical S...
05/28/2024 12:28:39

lululemon-athletica-was-among-the-worst-performing-stocks-last-week-may-19-may-26-2024-are-these-10-large-cap-stock-losers-in-your-portfolio
Lululemon Athletica Was Among The Worst-Pe...
05/26/2024 15:16:23

10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululem...

beigene-says-brukinsa-data-at-american-society-of-clinical-oncology-asco-annual-meeting-in-chicago-underscore-differentiated-clinical-profile-for-treatment-of-cll-and-sll
BeiGene Says BRUKINSA Data At American Soc...
05/24/2024 10:05:14

 The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inh...

beigene-to-highlight-new-hematology-portfolio-and-pipeline-data-at-eha2024-june-13-16-2024
BeiGene To Highlight New Hematology Portfo...
05/14/2024 20:16:58

Study evaluating BRUKINSA® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral p...

td-cowen-maintains-buy-on-beigene-raises-price-target-to-254
TD Cowen Maintains Buy on BeiGene, Raises ...
05/09/2024 16:16:07

TD Cowen analyst Yaron Werber maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $236 to $254.

beigene-q1-2024-gaap-epads-241-beats-289-estimate-sales-751652m-beat-676451m-estimate
BeiGene Q1 2024 GAAP EPADS $(2.41) Beats $...
05/08/2024 10:10:27

BeiGene (NASDAQ:BGNE) reported quarterly losses of $(2.41) per share which beat the analyst consensus estimate of $(2.89) by 16...

tracking-last-weeks-top-performers-are-these-15-large-cap-stocks-in-your-portfolio-april-21-27-2024
Tracking Last Week's Top Performers: Are T...
04/28/2024 22:18:08

Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation.

evaluating-beigene-insights-from-6-financial-analysts
Evaluating BeiGene: Insights From 6 Financ...
04/24/2024 18:01:41

td-cowen-maintains-buy-on-beigene-raises-price-target-to-236
TD Cowen Maintains Buy on BeiGene, Raises ...
04/24/2024 17:26:08

TD Cowen analyst Yaron Werber maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $235 to $236.

healthstream-reports-upbeat-results-joins-spotify-ryder-system-and-other-big-stocks-moving-higher-on-tuesday
HealthStream Reports Upbeat Results, Joins...
04/23/2024 14:50:19

the-european-commission-approves-beigenes-tislelizumab-for-non-small-cell-lung-cancer-across-three-indications-including-first-and-second-line-use
The European Commission Approves BeiGene's...
04/23/2024 10:08:22

b-of-a-securities-maintains-neutral-on-beigene-lowers-price-target-to-1643
B of A Securities Maintains Neutral on Bei...
04/08/2024 16:34:50

B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $179.3 to...

genfleet-therapeutics-announced-clinical-trial-collaboration-and-supply-agreement-with-beigene-switzerland-to-start-a-combination-study-of-gfh009-and-brukinsa-zanubrutinib-in-phase-1b2-trial-for-diffuse-large-b-cell-lymphoma
Genfleet Therapeutics Announced Clinical T...
03/28/2024 11:14:09

4-analysts-assess-beigene-what-you-need-to-know
4 Analysts Assess BeiGene: What You Need T...
03/27/2024 15:00:50

bernstein-maintains-market-perform-on-beigene-lowers-price-target-to-161
Bernstein Maintains Market Perform on BeiG...
03/27/2024 08:48:58

Bernstein analyst Rebecca Liang maintains BeiGene (NASDAQ:BGNE) with a Market Perform and lowers the price target from $196 ...

lululemon-issues-weak-outlook-joins-nike-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Lululemon Issues Weak Outlook, Joins Nike ...
03/22/2024 09:40:40

U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday.

fda-approves-beigenes-first-drug-candidate-produced-through-its-immuno-oncology-program-for-esophageal-cancer
FDA Approves BeiGene's First Drug Candidat...
03/15/2024 17:01:52

FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy...

beigene-secures-fda-approval-for-tevimbra-for-treatment-of-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-after-prior-chemotherapy
BeiGene Secures FDA Approval For TEVIMBRA ...
03/14/2024 20:29:34

TEVIMBRA will be available in the U.S. in the second half of 2024. The FDA is also reviewing Biologics License Applications (BL...

fda-approves-beigenes-tevimbra-as-of-march-13-2024
FDA Approves Beigene's Tevimbra As Of Marc...
03/14/2024 18:13:44

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761232

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)